SC
SCYX.US Scynexis Inc
- Market cap
- USD 28.9M
- P/E
- -
- P/B
- 0.54x
- ROE
- -50.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SCYX.US undervalued?
Graham numberThe Graham number of Scynexis Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scynexis Inc fundamental analysis
No fundamental analysis for Scynexis Inc yet.
Scynexis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS…
Full company profileScynexis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scynexis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 257K | 257K | 257K | 121K | 12.1M | 13.2M | 5.09M | 140M | 3.75M | 20.6M | 313K |
| Gross Profit | 257K | 257K | 257K | 121K | -303K | 12.9M | 4.46M | 125M | 3.75M | 20.6M | - |
| Operating Income | -27.8M | -26.3M | -30.0M | -48.9M | -51.1M | -60.8M | -85.8M | 72.7M | -37.1M | -16.1M | -46.0M |
| EBITDA | -29.5M | -23.2M | -17.1M | -51.4M | -55.8M | -32.9M | -60.1M | 70.9M | -18.6M | -8.12M | -29.8M |
| Net Income | -30.0M | -25.1M | -12.5M | -53.7M | -55.2M | -32.9M | -62.8M | 67.0M | -21.3M | -8.61M | -29.8M |
| EPS | -16 | -75 | -23 | -77 | -41 | -9.97 | -12 | 11 | -3.51 | -1.38 | -2.52 |
| Balance Sheet | |||||||||||
| Total Assets | 59.8M | 45.9M | 53.2M | 57.2M | 103M | 120M | 87.8M | 128M | 90.6M | 59.0M | 68.0M |
| Total Liabilities | 25.0M | 24.4M | 21.9M | 44.3M | 79.8M | 78.6M | 84.6M | 55.5M | 35.6M | 9.65M | 8.90M |
| Shareholders' Equity | 34.8M | 21.4M | 31.2M | 12.9M | 22.8M | 41.3M | 3.23M | 73.0M | 55.1M | 49.4M | 59.0M |
| Cash & Short-term Investments | 58.6M | 43.9M | 44.2M | 48.4M | 93.0M | 104M | 73.5M | 74.4M | 59.3M | 21.3M | 47.2M |
| Total Debt | 14.3M | 14.7M | 15.1M | 14.9M | 19.8M | 43.6M | 48.6M | 15.1M | 16.3M | 2.18M | 1.82M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.4M | -24.6M | -28.3M | -38.1M | -49.4M | -54.6M | -79.9M | 60.2M | -24.0M | -5.28M | -40.6M |
| Capital Expenditure | 27.0K | 2.00K | 565K | 4.00K | 4.00K | 1.17M | 9.00K | 60.2M | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -29.4M | -24.6M | -28.9M | -38.1M | -49.4M | -55.7M | -79.9M | 60.2M | -24.0M | -5.28M | -40.6M |
| Ratios | |||||||||||
| ROE | -86.1% | -117.0% | -39.9% | -416.5% | -242.5% | -79.7% | -1,942.7% | 91.9% | -38.7% | -17.4% | -50.5% |
| ROA | -50.2% | -54.7% | -23.4% | -94.0% | -53.8% | -27.4% | -71.5% | 52.2% | -23.5% | -14.6% | -43.9% |
| Net Profit Margin | -11,668.9% | -9,751.0% | -4,851.4% | -44,388.4% | -458.0% | -249.7% | -1,233.7% | 47.8% | -568.3% | -41.8% | -9,514.9% |
| Debt to Equity | 0.41x | 0.68x | 0.48x | 1.15x | 0.87x | 1.06x | 15.03x | 0.21x | 0.30x | 0.04x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scynexis Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 10.0M | 7.48 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:8 on Jun 1, 2026.
Who owns Scynexis Inc
- Insiders 2.05%
- Institutions 57.01%
- Public & others 40.94%
- Shares outstanding 9.95M
- Free float 7.35M
Top funds holding SCYX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 291K | 2.93% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 58.1K | 0.58% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 15.8K | 0.16% | 0.00% | Sep 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 15.5K | 0.16% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 15.3K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 5.26K | 0.05% | 0.00% | Aug 2026 |
| Dimensional US Small Cap ETF | 5.19K | 0.05% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 4.83K | 0.05% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 2.28K | 0.02% | 0.00% | Sep 2026 |
| Victory Extended Market Index | 1.09K | 0.01% | -0.73% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 936.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding SCYX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Great Point Partners LLC | 944K | 9.49% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 757K | 7.60% | -20.42% | Jun 2026 |
| Propel Bio Management LLC | 543K | 5.46% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 543K | 5.46% | 0.00% | Jun 2026 |
| Woodline Partners LP | 388K | 3.89% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 297K | 2.98% | +51.75% | Jun 2026 |
| Avidity Partners Management LP | 260K | 2.61% | -50.00% | Jun 2026 |
| Kingdon Capital Management LLC | 248K | 2.49% | 0.00% | Jun 2026 |
| Millennium Management LLC | 181K | 1.82% | +132.47% | Jun 2026 |
| Heights Capital Management Inc | 151K | 1.51% | -42.29% | Jun 2026 |
| Dafna Capital Management LLC | 136K | 1.37% | 0.00% | Jun 2026 |
| Empery Asset Management, LP | 126K | 1.27% | -45.25% | Jun 2026 |
| Acadian Asset Management LLC | 115K | 1.16% | -1.32% | Sep 2026 |
| Geode Capital Management, LLC | 82.1K | 0.82% | +35.03% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 58.0K | 0.58% | +105.44% | Jun 2026 |
| Renaissance Technologies Corp | 51.8K | 0.52% | -32.28% | Sep 2026 |
| ADAR1 Capital Management LLC | 49.4K | 0.50% | 0.00% | Jun 2026 |
| BlackRock Inc | 41.5K | 0.42% | 0.00% | Jun 2026 |
| Velan Capital Investment Management LP | 40.0K | 0.40% | 0.00% | Jun 2026 |
| Northern Trust Corp | 22.4K | 0.22% | +87.37% | Jun 2026 |
Scynexis Inc company profile
- Company name
- Scynexis Inc
- Ticker
- SCYX.US
- Exchange
- USA Stocks
- Listed since
- May 2, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 18
- Fiscal year end
- December
- Address
- 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
- Phone
- 201 884 5485
- Website
- scynexis.com
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Scynexis Inc management
6- Dr. David Gonzalez Angulo M.D.CEO, President & Director · born 1965
- Mr. Scott Sukenick J.D.Chief Legal Officer & Corporate Secretary · born 1978
- Mr. Sanjay S. Subramanian M.B.A., M.S.Chief Financial Officer · born 1976
- Ms. Daniella GiganteVice President of Human Resources & Information Technology
- Dr. Todd Minga M.D.Senior Vice President of Research & Development
- Dr. Rossana Ferrara-Pontoriero Ph.D.Senior Vice President of Business Development & Portfolio Management